Could a single dose of a vaccine give added protection to someone who has recovered from COVID-19?
Two new studies that have been vetted and published have shown promise in the Pfizer vaccination, according to multiple media reports.
The studies, one done by University College London and Public Health England, and the other, done by Imperial College London, are the “first fully vetted papers,” according to The New York Times.
They were both published late Thursday in the peer-reviewed medical journal The Lancet, The Hill reported.
The first study looked at 51 health professionals who have recovered from COVID-19 and half of whom had either a mild or asymptomatic infection. They had undergone routine antibody tests since March. They were all given a single dose of the Pfizer vaccine, which was shown to increase their antibody levels 140 times, the Times reported.
The other study followed 72 health workers who were vaccinated in December, a third of whom had shown signs of being infected before.
The single dose showed “very strong” antibody and T-cell responses, the Times reported.
The findings could help speed up the distribution of vaccines and could help reduce variants from emerging, The Hill reported.
More coronavirus pandemic coverage:
>> Coronavirus vaccines: CDC separates myths from facts
>> Coronavirus: Should we be wearing two masks when we go out in public?
>> Coronavirus: How long between exposure to the virus and the start of symptoms?
>> Wash your masks: How to clean a cloth face covering
>> Fact check: Will masks lower the oxygen level, raise the carbon dioxide in your blood?
>> How to not let coronavirus pandemic fatigue set in, battle back if it does
Cox Media Group
